These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 7492098)
1. Cross-resistance to polyene and azole drugs in Cryptococcus neoformans. Joseph-Horne T; Hollomon D; Loeffler RS; Kelly SL Antimicrob Agents Chemother; 1995 Jul; 39(7):1526-9. PubMed ID: 7492098 [TBL] [Abstract][Full Text] [Related]
2. Amphotericin B resistant isolates of Cryptococcus neoformans without alteration in sterol biosynthesis. Joseph-Horne T; Loeffler RS; Hollomon DW; Kelly SL J Med Vet Mycol; 1996; 34(3):223-5. PubMed ID: 8803806 [TBL] [Abstract][Full Text] [Related]
3. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Ernst EJ; Klepser ME; Pfaller MA Antimicrob Agents Chemother; 2000 Apr; 44(4):1108-11. PubMed ID: 10722525 [TBL] [Abstract][Full Text] [Related]
4. Fluconazole tolerance in clinical isolates of Cryptococcus neoformans. Venkateswarlu K; Taylor M; Manning NJ; Rinaldi MG; Kelly SL Antimicrob Agents Chemother; 1997 Apr; 41(4):748-51. PubMed ID: 9087482 [TBL] [Abstract][Full Text] [Related]
5. Identification and properties of plasma membrane azole efflux pumps from the pathogenic fungi Cryptococcus gattii and Cryptococcus neoformans. Basso LR; Gast CE; Bruzual I; Wong B J Antimicrob Chemother; 2015 May; 70(5):1396-407. PubMed ID: 25630649 [TBL] [Abstract][Full Text] [Related]
6. Sterol compositions and susceptibilities to amphotericin B of environmental Cryptococcus neoformans isolates are changed by murine passage. Currie B; Sanati H; Ibrahim AS; Edwards JE; Casadevall A; Ghannoum MA Antimicrob Agents Chemother; 1995 Sep; 39(9):1934-7. PubMed ID: 8540694 [TBL] [Abstract][Full Text] [Related]
7. Antiphagocytic protein 1 increases the susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole. Ghaffar M; Orr C; Webb G PLoS One; 2019; 14(12):e0225701. PubMed ID: 31800598 [TBL] [Abstract][Full Text] [Related]
8. Antifungal drug resistance in pathogenic fungi. Vanden Bossche H; Dromer F; Improvisi I; Lozano-Chiu M; Rex JH; Sanglard D Med Mycol; 1998; 36 Suppl 1():119-28. PubMed ID: 9988500 [TBL] [Abstract][Full Text] [Related]
9. In vivo and in vitro antifungal activity of the polyene derivative SPA-S-753 against encapsulated form of Cryptococcus neoformans. Strippoli V; D'Auria FD; Simonetti N; Basti D; Bruzzese T Infection; 1997; 25(1):27-31. PubMed ID: 9039534 [TBL] [Abstract][Full Text] [Related]
10. Multi-azole-resistant strains of Cryptococcus neoformans var. grubii isolated from a FLZ-resistant strain by culturing in medium containing voriconazole. Kano R; Okubo M; Hasegawa A; Kamata H Med Mycol; 2017 Nov; 55(8):877-882. PubMed ID: 28927230 [TBL] [Abstract][Full Text] [Related]
11. Antifungal susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole. Khyriem AB; Sujatha S; Parija SC Indian J Pathol Microbiol; 2006 Apr; 49(2):307-8. PubMed ID: 16933750 [TBL] [Abstract][Full Text] [Related]
12. In vitro antifungal synergy between amphiphilic aminoglycoside K20 and azoles against Candida species and Cryptococcus neoformans. Shrestha SK; Grilley M; Anderson T; Dhiman C; Oblad J; Chang CW; Sorensen KN; Takemoto JY Med Mycol; 2015 Nov; 53(8):837-44. PubMed ID: 26260746 [TBL] [Abstract][Full Text] [Related]
13. A defect in iron uptake enhances the susceptibility of Cryptococcus neoformans to azole antifungal drugs. Kim J; Cho YJ; Do E; Choi J; Hu G; Cadieux B; Chun J; Lee Y; Kronstad JW; Jung WH Fungal Genet Biol; 2012 Nov; 49(11):955-66. PubMed ID: 22975303 [TBL] [Abstract][Full Text] [Related]
14. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark. Hagen F; Hare Jensen R; Meis JF; Arendrup MC Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834 [TBL] [Abstract][Full Text] [Related]
15. First Isolation of Azole-Resistant Cryptococcus neoformans from Feline Cryptococcosis. Kano R; Okubo M; Yanai T; Hasegawa A; Kamata H Mycopathologia; 2015 Dec; 180(5-6):427-33. PubMed ID: 26162642 [TBL] [Abstract][Full Text] [Related]
16. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Franzot SP; Casadevall A Antimicrob Agents Chemother; 1997 Feb; 41(2):331-6. PubMed ID: 9021188 [TBL] [Abstract][Full Text] [Related]
17. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods. Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975 [TBL] [Abstract][Full Text] [Related]
18. Relationship between polyene resistance and sterol compositions in Cryptococcus neoformans. Kim SJ; Kwon-Chung J; Milne GW; Hill WB; Patterson G Antimicrob Agents Chemother; 1975 Jan; 7(1):99-106. PubMed ID: 1094946 [TBL] [Abstract][Full Text] [Related]
19. Effects of three azole derivatives on the lipids of different strains of Cryptococcus neoformans. Franzot SP; Hamdan JS Mycoses; 1995; 38(5-6):183-9. PubMed ID: 8531929 [TBL] [Abstract][Full Text] [Related]
20. 3-Bromopyruvate: a novel antifungal agent against the human pathogen Cryptococcus neoformans. Dyląg M; Lis P; Niedźwiecka K; Ko YH; Pedersen PL; Goffeau A; Ułaszewski S Biochem Biophys Res Commun; 2013 May; 434(2):322-7. PubMed ID: 23541578 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]